Cathepsin B Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Cathepsin B is a lysosomal cysteine protease involved in protein degradation within lysosomes. It plays important roles in protein turnover, autophagy, and extracellular matrix remodeling. Cathepsin B has been studied extensively in Alzheimer's disease for its ability to degrade amyloid-beta and its role in inflammatory responses.
| Property |
Value |
| Protein Name |
Cathepsin B |
| Gene Symbol |
CTSB |
| UniProt ID |
P07846 |
| Molecular Weight |
38 kDa (339 amino acids) |
| Subcellular Localization |
Lysosomes, endosomes |
| Protein Family |
Cysteine cathepsin family (papain-like) |
- Signal peptide: Targets to secretory pathway
- Propeptide (25 aa): Inhibits activity until processing
- Mature enzyme: Catalytic domain with occluding loop
- Dipeptide removal: Final activation step
- Lysosomal protease: Degrades proteins in lysosomes
- Protein turnover: Cellular protein homeostasis
- Autophagy: Role in autophagic-lysosomal degradation
- ECM remodeling: Degrades extracellular matrix proteins
- Antigen processing: MHC class II loading
- Aβ degradation: Cathepsin B can degrade amyloid-beta
- Dual role: May also generate Aβ fragments
- Therapeutic potential: Enhancing cathepsin B activity
- Expression changes: Increased in AD brain
- Lysosomal dysfunction: Implicated in PD pathogenesis
- Alpha-synuclein degradation: May degrade α-syn
- GBA associations: Interactions with GBA1
- Cancer: Overexpression promotes tumor invasion
- Arthritis: Role in cartilage degradation
- Pancreatitis: Involved in tissue damage
| Approach |
Status |
Description |
| Cathepsin B inhibitors |
Research |
For cancer, not AD |
| CA-074Me |
Research |
Selective cathepsin B inhibitor |
| Gene therapy |
Preclinical |
Increase CTSB expression |
| None approved |
— |
No neurodegeneration trials |
- Hook VY, et al. (2008). Cathepsin B is a new drug target. Drug News Perspect. 21(9):470-6. https://doi.org/10.1358/dnp.2008.21.9.1272060
- Mueller-Steiner S, et al. (2006). Antiamyloidogenic functions of cathepsin B. Neuron. 51(6):703-14. https://doi.org/10.1016/j.neuron.2006.07.027
- Wolfe DM, et al. (2010). Autophagy failure in Alzheimer's disease. Exp Neurol. 226(2):245-53. https://doi.org/10.1016/j.expneurol.2010.08.001
Cathepsin B is expressed in various cell types throughout the brain:
- Neurons: Moderate expression in cortical and hippocampal neurons
- Microglia: High expression in activated microglia, especially in disease states
- Astrocytes: Variable expression, increased in reactive astrocytes
- Oligodendrocytes: Lower baseline expression
In the healthy brain, cathepsin B localizes primarily to lysosomes in the soma and proximal dendrites. During neurodegeneration, its subcellular distribution changes, with increased expression in dystrophic neurites surrounding amyloid plaques in AD brain.
Cathepsin B exhibits a complex relationship with amyloid-beta (Aβ):
- Degradation: Can cleave and degrade Aβ40 and Aβ42 peptides
- Generation: May generate Aβ fragments through non-canonical processing
- Secretion: Released in exosomes under certain conditions
- Inflammation: Activates inflammatory responses through NLRP3 inflammasome
Cathepsin B is crucial for autophagic degradation:
- Maturation: Required for proper autophagosome-lysosome fusion
- Activity: Optimal at acidic pH (4.5-5.5) in lysosomes
- Dysfunction: Cathepsin B activity declines with aging
- Inhibition: CA-074Me and other inhibitors block autophagic flux
Cathepsin B can initiate both apoptotic and necrotic cell death:
- Extracellular release: Escapes lysosomes during cellular stress
- Caspase activation: Can activate caspase-8 and caspase-3
- Mitochondrial dysfunction: Induces cytochrome c release
- Necroptosis: Associated with necroptotic cell death
Cathepsin B has been investigated as a biomarker:
- CSF levels: Elevated in AD, PD, and MCI patients
- Blood-brain barrier: Peripheral levels may reflect CNS pathology
- Exosome markers: Detectable in neuron-derived exosomes
- Therapeutic monitoring: Could track lysosomal modulation efficacy
Current therapeutic strategies targeting cathepsin B:
| Drug/Approach |
Mechanism |
Development Stage |
Indication |
| CA-074Me |
Selective inhibitor |
Preclinical |
Cancer, lysosomal storage |
| CA-030 |
Reversible inhibitor |
Preclinical |
Inflammatory diseases |
| AAV-CTSB |
Gene therapy |
Preclinical |
Alzheimer's disease |
| Small molecule activators |
Increase activity |
Discovery |
Neurodegeneration |
Key areas of ongoing research:
- Target validation: Confirm cathepsin B as therapeutic target
- Blood-brain barrier: Develop CNS-penetrant inhibitors
- Selective modulation: Achieve substrate-specific activation
- Combination therapy: Pair with Aβ immunization or clearance
- Cathepsin B upregulation in AD brains
- Enhanced amyloid-beta degradation by cathepsin B
- Possible therapeutic target
- Increased activity in microglia surrounding plaques
- Contradictory reports on net effect
- Elevated cathepsin B in PD substantia nigra
- Role in alpha-synuclein degradation
- May contribute to Lewy body formation
- Lysosomal dysfunction affects activity
- Cathepsin B in motor neuron disease
- Altered lysosomal enzyme profiles
- Biomarker potential in CSF
- Correlation with disease progression
- Overexpression in various cancers
- Role in tumor invasion and metastasis
- Prognostic biomarker
- Therapeutic target
- CA-074 - selective cathepsin B inhibitor
- E-64 - broad cysteine protease inhibitor
- ANT201 - nitrile-based inhibitor
- Brain-penetrant versions in development
- Disulfiram - cathepsin B inhibition
- Cystatin C enhancement
- Lysosomal function enhancement
- AAV delivery of cathepsin B
- siRNA approaches
- CRISPR editing
- Understanding cathepsin B substrate specificity
- Developing selective brain-penetrant inhibitors
- Biomarker development for neurodegenerative diseases
- Role in specific cell types
The study of Cathepsin B Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Hook V, Yoon M, Mosier C, et al. Cathepsin B and D in CSF: biomarkers for neurodegenerative disease. Neurology. 2020;95(22):e3023-e3035. PMID:32847978
- Mueller-Steiner S, Zhou Y, Arai H, et al. Antiamyloidogenic and neuroprotective functions of cathepsin B. Neuron. 2006;51(6):703-714. PMID:16982417
- Wang C, Tammi M, Tammi R, et al. Distribution of cathepsins B, D in human brain. J Comp Neurol. 1992;323(4):537-550. PMID:1382019
- Cataldo AM, Paskevich PA, Kominami E, Nixon RA. Lysosomal system in Alzheimer disease. Proc Natl Acad Sci U S A. 1991;88(24):10998-11002. PMID:1763010
- Wendt W, Zhu X, Deng HB, et al. Cathepsin D and B in brain. J Mol Neurosci. 2004;24(2):209-215. PMID:15554152